Pediatric oncology

Current Opinion in Chemical Biology

Volumn 11, Issue 4, 2007, Pages 424-432

  Kurmasheva, Raushan T ^a   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 5 AZA 2' DEOXYCYTIDINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AAL 881; AG 13925; AG 538; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BMS 582664; BORTEZOMIB; C 100; CD135 ANTIGEN; CEP 701; CILENGITIDE; DASATINIB; DEPSIPEPTIDE; EMD 273063; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPRATUZUMAB; ERLOTINIB; EVEROLIMUS; GEFITINIB; GFA 116; GW 786024; IMATINIB; IMC 1121B; IMCA 12; INTERLEUKIN 13; ISPINESIB; IXABEPILONE; KRN 951; LAPATINIB; LENALIDOMIDE; MIDOSTAURIN; MLN 18; N (3 METHOXYBENZYL) 3,3 DIMETHYL N [1 (3,4 METHYLENEDIOXYBENZYL) 2 (1 PIPERAZINYLCARBONYL) 4 PYRROLIDINYL]BUTYRAMIDE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NOTCH1 RECEPTOR; OBLIMERSEN; PD 332991; PEMETREXED; PHA 665752; SEMAXANIB; SOMATOMEDIN C RECEPTOR; SORAFENIB; SU 11657; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VATALANIB; VORINOSTAT; XL 880;

ACUTE LYMPHOBLASTIC LEUKEMIA; BASAL CELL NEVUS SYNDROME; BRAIN CANCER; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; DIGESTIVE SYSTEM CANCER; DISEASE FREE INTERVAL; EWING SARCOMA; GLIOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; NEPHROBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CHILD; CHROMOSOMES, HUMAN; GENE EXPRESSION REGULATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 34548119857     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2007.05.037     Document Type: Review

References (64)

1. Ries L.A., Eisner M.P., Kosary C.L., Hankey B.F., Miller B.A., Clegg L., Mariotto A., Feuer E.J., and Edwards BK. SEER Cancer Statistics Review 1975-2002 (2005), National Cancer Institute BM
2. Horowitz M.E., Etcubanas E., Christensen M.L., Houghton J.A., George S.L., Green A.A., and Houghton P.J. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 6 (1988) 308-314
3. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 4 (2005) 219-234. This article presents a comprehensive review of the activity, toxicities, and long-term sequellae associated with drugs that target DNA topoisomerase II.
4. Relling M.V., Rubnitz J.E., Rivera G.K., Boyett J.M., Hancock M.L., Felix C.A., Kun L.E., Walter A.W., Evans W.E., and Pui C.H. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354 (1999) 34-39
5. Nygren P., Sorbye H., Osterlund P., and Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. Acta Oncol 44 (2005) 203-217. This article is a comprehensive and critical analysis of the activity of chemotherapeutic regimens and the impact of bevacizumab (Avastin) in colon cancer.
6. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64. This article is an editorial in which the authors bring together disparate evidence to suggest that cancer cells may become 'addicted' to events in malignant transformation. For example, cancer cells require a greater amount of cyclin D1 to maintain their malignant phenotype than did cancer cells that never overexpressed cyclin D1. In these tumors, targeting the 'addicted' pathway induces differentiation or apoptosis.
7. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91 (2004) 1-30
8. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
9. She Q.B., Solit D.B., Ye Q., O'Reilly K.E., Lobo J., and Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8 (2005) 287-297. This important paper shows that the status of PTEN determines the cellular response to ErbB1 inhibitors. Both ErbB1 and Akt signal to inactivate the proapoptotic protein BAD, and inhibition of both pathways is required to prevent BAD phosphorylation and induce apoptosis.
10. Sosman J.A., Puzanov I., and Atkins M.B. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 13 (2007) 764s-769s
11. Stein R.C., and Waterfield M.D. PI3-kinase inhibition: a target for drug development?. Mol Med Today 6 (2000) 347-357
12. Knight Z.A., Chiang G.G., Alaimo P.J., Kenski D.M., Ho C.B., Coan K., Abraham R.T., and Shokat K.M. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 12 (2004) 4749-4759
13. Woods K.W., Fischer J.P., Claiborne A., Li T., Thomas S.A., Zhu G.D., Diebold R.B., Liu X., Shi Y., Klinghofer V., et al. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorg Med Chem 14 (2006) 6832-6846
14. Luo Y., Shoemaker A.R., Liu X., Woods K.W., Thomas S.A., de Jong R., Han E.K., Li T., Stoll V.S., Powlas J.A., et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4 (2005) 977-986
15. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
16. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., Sausville E.A., and Roy K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2 (2003) 1093-1103
17. Hideshima T., Catley L., Yasui H., Ishitsuka K., Raje N., Mitsiades C., Podar K., Munshi N.C., Chauhan D., Richardson P.G., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107 (2006) 4053-4062
18. Mistry A.R., Pedersen E.W., Solomon E., and Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 17 (2003) 71-97
19. Brown P., and Small D. FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. Eur J Cancer 40 (2004) 707-721 discussion 722-704. This is a comprehensive review of FLT3 biology, and mutations in adult and childhood leukemias. The review focuses on agents that target FLT3, and the potential for design of rational combination therapies.
20. Kiyoi H., Towatari M., Yokota S., Hamaguchi M., Ohno R., Saito H., and Naoe T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12 (1998) 1333-1337
21. Kiyoi H., Ohno R., Ueda R., Saito H., and Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21 (2002) 2555-2563
22. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., Asou N., Kuriyama K., Yagasaki F., Shimazaki C., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97 (2001) 2434-2439
23. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Care R.S., Peake I.R., and Reilly J.T. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 113 (2001) 983-988
24. Xu F., Taki T., Yang H.W., Hanada R., Hongo T., Ohnishi H., Kobayashi M., Bessho F., Yanagisawa M., and Hayashi Y. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol 105 (1999) 155-162
25. Nakao M., Janssen J.W., Erz D., Seriu T., and Bartram C.R. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease. Leukemia 14 (2000) 522-524
26. Smith B.D., Levis M., Beran M., Giles F., Kantarjian H., Berg K., Murphy K.M., Dauses T., Allebach J., and Small D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
27. Zhao M., Kiyoi H., Yamamoto Y., Ito M., Towatari M., Omura S., Kitamura T., Ueda R., Saito H., and Naoe T. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia 14 (2000) 374-378
28. George P., Bali P., Cohen P., Tao J., Guo F., Sigua C., Vishvanath A., Fiskus W., Scuto A., Annavarapu S., et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 64 (2004) 3645-3652
29. Yao Q., Nishiuchi R., Kitamura T., and Kersey J.H. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway. Leukemia 19 (2005) 1605-1612
30. Weng A.P., Ferrando A.A., Lee W., Morris J.P.T., Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., and Aster J.C. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306 (2004) 269-271. This is the first report of activating mutations in NOTCH1 in leukemia and forms the basis for evaluating γ-secretase inhibitors in T cell ALL.
31. Aster J.C. Deregulated NOTCH signaling in acute T-cell lymphoblastic leukemia/lymphoma: new insights, questions, and opportunities. Int J Hematol 82 (2005) 295-301
32. Curry C.L., Reed L.L., Golde T.E., Miele L., Nickoloff B.J., and Foreman K.E. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 24 (2005) 6333-6344
33. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., Engstrom L., Pinzon-Ortiz M., Fine J.S., Lee H.J., et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279 (2004) 12876-12882
34. Albritton K.H., and Randall R.L. Prospects for targeted therapy of synovial sarcoma. J Pediatr Hematol Oncol 27 (2005) 219-222
35. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681. This paper reports the first BH3 domain mimetic that inhibits the function of BCL2-family of anti-apoptotic proteins. The work demonstrates single agent activity against lymphomas, and small cell lung cancer lines in vitro and in vivo.
36. Petros A.M., Dinges J., Augeri D.J., Baumeister S.A., Betebenner D.A., Bures M.G., Elmore S.W., Hajduk P.J., Joseph M.K., Landis S.K., et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 49 (2006) 656-663
37. Strammiello R., Benini S., Manara M.C., Perdichizzi S., Serra M., Spisni E., Picci P., and Scotlandi K. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. Horm Metab Res 35 (2003) 675-684
38. MacEwen E.G., Pastor J., Kutzke J., Tsan R., Kurzman I.D., Thamm D.H., Wilson M., and Radinsky R. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92 (2004) 77-91
39. Braczkowski R., Schally A.V., Plonowski A., Varga J.L., Groot K., Krupa M., and Armatis P. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 95 (2002) 1735-1745
40. Cohen B.D., Baker D.A., Soderstrom C., Tkalcevic G., Rossi A.M., Miller P.E., Tengowski M.W., Wang F., Gualberto A., Beebe J.S., et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11 (2005) 2063-2073
41. Kurmasheva R.T., and Houghton P.J. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766 (2006) 1-22
42. Wang Y., Hailey J., Williams D., Wang Y., Lipari P., Malkowski M., Wang X., Xie L., Li G., Saha D., et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 4 (2005) 1214-1221
43. Sachdev D., and Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 11 (2006) 27-39
44. Sachdev D., and Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6 (2007) 1-12. This is a comprehensive review of the role of IGFs in cancer and is a description of current strategies to disrupt IGF signaling, highlighting some of the key issues to be considered in design and interpretation of clinical trials with agents targeting the IGF-I receptor.
45. Guerreiro A.S., Boller D., Doepfner K.T., and Arcaro A. IGF-IR: potential role in antitumor agents. Drug News Perspect 19 (2006) 261-272
46. Scotlandi K., Manara M.C., Nicoletti G., Lollini P.L., Lukas S., Benini S., Croci S., Perdichizzi S., Zambelli D., Serra M., et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65 (2005) 3868-3876
47. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Akiyama M., Hideshima T., Chauhan D., Joseph M., Libermann T.A., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 (2004) 221-230
48. Haluska P., Carboni J.M., Loegering D.A., Lee F.Y., Wittman M., Saulnier M.G., Frennesson D.B., Kalli K.R., Conover C.A., Attar R.M., et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66 (2006) 362-371
49. Gable K.L., Maddux B.A., Penaranda C., Zavodovskaya M., Campbell M.J., Lobo M., Robinson L., Schow S., Kerner J.A., Goldfine I.D., et al. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther 5 (2006) 1079-1086
50. Wittman M.D., Balasubramanian B., Stoffan K., Velaparthi U., Liu P., Krishnanathan S., Carboni J., Li A., Greer A., Attar R., et al. Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase. Bioorg Med Chem Lett 17 (2007) 974-977
51. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
52. Bailly R.A., Bosselut R., Zucman J., Cormier F., Delattre O., Roussel M., Thomas G., and Ghysdael J. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 14 (1994) 3230-3241
53. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
54. Gorlin R.J. Nevoid basal cell carcinoma syndrome. Dermatol Clin 13 (1995) 113-125
55. Wechsler-Reya R., and Scott M.P. The developmental biology of brain tumors. Annu Rev Neurosci 24 (2001) 385-428
56. Lee Y., Miller H.L., Jensen P., Hernan R., Connelly M., Wetmore C., Zindy F., Roussel M.F., Curran T., Gilbertson R.J., et al. A molecular fingerprint for medulloblastoma. Cancer Res 63 (2003) 5428-5437
57. Chen J.K., Taipale J., Young K.E., Maiti T., and Beachy P.A. Small molecule modulation of smoothened activity. Proc Natl Acad Sci USA 99 (2002) 14071-14076. This is the first report of a small molecule, cyclopamine, inhibiting the SMO pathway.
58. Romer J.T., Kimura H., Magdaleno S., Sasai K., Fuller C., Baines H., Connelly M., Stewart C.F., Gould S., Rubin L.L., et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 6 (2004) 229-240
59. Williams J.A., Guicherit O.M., Zaharian B.I., Xu Y., Chai L., Wichterle H., Kon C., Gatchalian C., Porter J.A., Rubin L.L., et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci USA 100 (2003) 4616-4621
60. Kranenburg O., Scharnhorst V., Van der Eb A.J., and Zantema A. Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J Cell Biol 131 (1995) 227-234
61. Saab R., Bills J.L., Miceli A.P., Anderson C.M., Khoury J.D., Fry D.W., Navid F., Houghton P.J., and Skapek S.X. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther 5 (2006) 1299-1308
62. Burkhart C.A., Cheng A.J., Madafiglio J., Kavallaris M., Mili M., Marshall G.M., Weiss W.A., Khachigian L.M., Norris M.D., and Haber M. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 95 (2003) 1394-1403
63. Chesler L., Schlieve C., Goldenberg D.D., Kenney A., Kim G., McMillan A., Matthay K.K., Rowitch D., and Weiss W.A. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66 (2006) 8139-8146. This work demonstrates that the stability of MYCN is regulated through Akt phosphorylation and inactivation of GSK3β. In MYCN-driven neuroblastoma, inhibition of PI3K decreased MYCN protein and inhibited tumor growth. The work suggests that agents that inactivate PI3K, Akt, or GSK3β could be effective in cancers that overexpress MYCN.
64. O'Neill D.J., Shen L., Prouty C., Conway B.R., Westover L., Xu J.Z., Zhang H.C., Maryanoff B.E., Murray W.V., Demarest K.T., et al. Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Bioorg Med Chem 12 (2004) 3167-3185